Drug intelligence / Profile preview

RLD-2209

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

RLD-2209 is a Hanmi-developed oral small-molecule antihypertensive investigational product. It has been evaluated as an active comparator in a multicenter randomized double-blind Phase 3 study in adults with essential hypertension, using sequential oral regimens designated RLD2209-1 and RLD2209-2. Publicly available trial materials do not disclose its chemical identity, active ingredients, molecular target, or detailed mechanism of action.

Beyond the preview

Go deeper on RLD-2209.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RLD-2209.

Explore the full profile